The optimal regimen for adjuvant treatment has not been established in GC yet. We plan to compare TS-1, TS-1/oxaliplatin with or without RT in D2 resected gastric cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
547
Samsung Medical Center
Seoul, South Korea
The primary endpoint of the study is disease-free survival (DFS).
Time frame: 3-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.